JOHNSON & JOHNSON (JNJ) Insider Transactions
Over the last 12 months, 22 JOHNSON & JOHNSON (JNJ) insiders filed 255 SEC Form 4 transactions — $257.7K in open-market purchases ( 1 distinct buyers) and $125.8M in open-market sales. 0% of all transactions were executed under a pre-scheduled Rule 10b5-1 trading plan.
- $257.7KOpen-market buys (1y)
- $125.8MOpen-market sells (1y)
- 22Distinct insiders
- 255Transactions filed
- 0%Under Rule 10b5-1 plan
- 2026-06-11Latest filing
Recent Form 4 Filings Most recent 50 of 255 (1-year window)
Each row is a single Form 4 filing event for JNJ, sourced directly from SEC EDGAR. The Type column classifies the SEC transaction code into Buy / Sell / Grant / Exercise / Other; the 10b5-1 badge marks trades executed under a pre-scheduled SEC Rule 10b5-1 plan.
| Date | Insider | Title | Type | SEC Code | Value | Shares | Price |
|---|---|---|---|---|---|---|---|
| 2026-06-11 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Exercise | M | $1.2M | 10,000 | $115.67 |
| 2026-06-11 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Exercise | M | $0 | 10,000 | $0.00 |
| 2026-06-11 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Sell | S | $2.4M | 10,000 | $241.15 |
| 2026-06-09 | Woods Eugene A. | — | Grant | A | $37.5K | 161 | $232.79 |
| 2026-06-09 | Pinto Daniel E | — | Grant | A | $31.2K | 134 | $232.79 |
| 2026-06-09 | HEWSON MARILLYN A | — | Grant | A | $50.0K | 215 | $232.79 |
| 2026-05-01 | REED JOHN C | EVP, Innovative Medicine, R&D | Exercise | M | $0 | 25,255 | $0.00 |
| 2026-05-01 | REED JOHN C | EVP, Innovative Medicine, R&D | Exercise | M | $0 | 25,255 | $0.00 |
| 2026-05-01 | REED JOHN C | EVP, Innovative Medicine, R&D | Other | F | $2.5M | 11,002 | $229.85 |
| 2026-04-23 | Woods Eugene A. | — | Grant | A | $0 | 975 | $0.00 |
| 2026-04-23 | West Nadja | — | Grant | A | $0 | 975 | $0.00 |
| 2026-04-23 | WEINBERGER MARK A | — | Grant | A | $0 | 975 | $0.00 |
| 2026-04-23 | Pinto Daniel E | — | Grant | A | $0 | 1,712 | $0.00 |
| 2026-04-23 | MORIKIS JOHN G | — | Grant | A | $0 | 1,540 | $0.00 |
| 2026-04-23 | McClellan Mark B. | — | Grant | A | $0 | 975 | $0.00 |
| 2026-04-23 | Joly Hubert | — | Grant | A | $0 | 975 | $0.00 |
| 2026-04-23 | Johnson Paula A | — | Grant | A | $0 | 975 | $0.00 |
| 2026-04-23 | HEWSON MARILLYN A | — | Grant | A | $0 | 975 | $0.00 |
| 2026-04-23 | Doudna Jennifer A | — | Grant | A | $0 | 975 | $0.00 |
| 2026-04-23 | Beckerle Mary C | — | Grant | A | $0 | 975 | $0.00 |
| 2026-03-10 | HEWSON MARILLYN A | — | Grant | — | $50.0K | 206 | $242.14 |
| 2026-03-10 | Pinto Daniel E | — | Grant | — | $31.3K | 129 | $242.14 |
| 2026-03-10 | Woods Eugene A. | — | Grant | — | $37.5K | 155 | $242.14 |
| 2026-02-27 | Decker Robert J | VP Corporate Controller | Grant | — | $471.4K | 4,075 | $115.67 |
| 2026-02-27 | Decker Robert J | VP Corporate Controller | Grant | — | $0 | 4,075 | $0.00 |
| 2026-02-27 | Decker Robert J | VP Corporate Controller | Sell | — | $1.0M | 4,075 | $247.87 |
| 2026-02-20 | Schmid Timothy | EVP, WW Chair, MedTech | Sell | — | $324.8K | 1,322 | $245.66 |
| 2026-02-18 | Schmid Timothy | EVP, WW Chair, MedTech | Grant | — | $1.6M | 13,625 | $115.67 |
| 2026-02-18 | Schmid Timothy | EVP, WW Chair, MedTech | Grant | — | $1.2M | 8,998 | $129.51 |
| 2026-02-18 | Schmid Timothy | EVP, WW Chair, MedTech | Grant | — | $0 | 13,625 | $0.00 |
| 2026-02-18 | Schmid Timothy | EVP, WW Chair, MedTech | Grant | — | $0 | 8,998 | $0.00 |
| 2026-02-18 | Schmid Timothy | EVP, WW Chair, MedTech | Sell | — | $3.3M | 13,625 | $244.20 |
| 2026-02-18 | Schmid Timothy | EVP, WW Chair, MedTech | Sell | — | $2.2M | 8,998 | $244.53 |
| 2026-02-17 | Swanson James D. | EVP, CIO | Grant | — | $3.4M | 20,521 | $164.62 |
| 2026-02-17 | Swanson James D. | EVP, CIO | Grant | — | $0 | 20,521 | $0.00 |
| 2026-02-17 | Wolk Joseph J | Exec VP, CFO | Grant | — | $2.2M | 19,241 | $115.67 |
| 2026-02-17 | Wolk Joseph J | Exec VP, CFO | Grant | — | $1.6M | 12,066 | $129.51 |
| 2026-02-17 | Wolk Joseph J | Exec VP, CFO | Grant | — | $4.4M | 33,386 | $131.94 |
| 2026-02-17 | Wolk Joseph J | Exec VP, CFO | Grant | — | $0 | 19,241 | $0.00 |
| 2026-02-17 | Wolk Joseph J | Exec VP, CFO | Grant | — | $0 | 12,066 | $0.00 |
| 2026-02-17 | Wolk Joseph J | Exec VP, CFO | Grant | — | $0 | 33,386 | $0.00 |
| 2026-02-17 | REED JOHN C | EVP, Innovative Medicine, R&D | Grant | — | $3.4M | 21,721 | $157.92 |
| 2026-02-17 | REED JOHN C | EVP, Innovative Medicine, R&D | Grant | — | $4.7M | 29,927 | $156.15 |
| 2026-02-17 | REED JOHN C | EVP, Innovative Medicine, R&D | Grant | — | $0 | 21,721 | $0.00 |
| 2026-02-17 | REED JOHN C | EVP, Innovative Medicine, R&D | Grant | — | $0 | 29,927 | $0.00 |
| 2026-02-17 | Swanson James D. | EVP, CIO | Sell | — | $5.0M | 20,521 | $242.70 |
| 2026-02-17 | Wolk Joseph J | Exec VP, CFO | Sell | — | $4.7M | 19,241 | $242.99 |
| 2026-02-17 | Wolk Joseph J | Exec VP, CFO | Sell | — | $2.9M | 12,066 | $242.87 |
| 2026-02-17 | Wolk Joseph J | Exec VP, CFO | Sell | — | $8.1M | 33,386 | $242.75 |
| 2026-02-17 | Wolk Joseph J | Exec VP, CFO | Sell | — | $6.1M | 24,961 | $242.68 |
Showing the most recent 50 of 255 transactions. For the full 1-year history with sorting, filtering, and cross-ticker industry context, open the full insider transactions drilldown.
Top Insider Buyers of JNJ By dollar volume, 1-year window
- MORIKIS JOHN G $257.7K
Methodology & FAQ
How We Track JNJ Insider Transactions
Form 4 disclosures are sourced directly from SEC EDGAR and re-ingested on every pipeline cycle. A complete description of transaction-code handling, the open-market vs grant distinction, and the Rule 10b5-1 plan-reference heuristic is documented in the Methodology.
What is an SEC Form 4 filing for JOHNSON & JOHNSON?
Form 4 is a transaction-level disclosure that corporate insiders — officers, directors, and beneficial owners of more than 10% of a registered class of equity securities — must file with the SEC within two business days of any change in their beneficial ownership of JOHNSON & JOHNSON (JNJ) shares.
What is a Rule 10b5-1 trading plan?
Rule 10b5-1 is an SEC rule that lets insiders schedule trades in advance under a written plan, providing an affirmative defense against insider-trading allegations as long as the plan was adopted in good faith and not while in possession of material non-public information. Form 4 rows marked "10b5-1" on this page indicate the underlying trade was executed under such a plan; rows without the badge are discretionary or did not reference a plan in the Form 4 footnotes.
How is "insider buying" different from a stock grant or option exercise?
An insider buy (SEC transaction code P) is an open-market purchase of JOHNSON & JOHNSON (JNJ) stock executed at the prevailing market price using the insider's personal capital. Stock grants (code A) and option exercises (code M) are compensation events, not directional trades; they are tracked separately and excluded from the "conviction" signal because they are not discretionary purchases.
How recent is the data?
Form 4 transactions are typically reported within two business days of execution. Pactolio re-ingests the EDGAR feed on a nightly cycle and reflects new filings on the next ingest run, typically within 24 hours of EDGAR acceptance. The table on this page covers the most recent 1-year window.